AbbVie, the global biopharmaceutical company, has issued patent infringement accusations against Sandoz and several other pharmaceutical companies. Allegedly, these companies have infringed a substantial number of AbbVie’s patents when developing their generic versions of Rinvoq, AbbVie’s notable immunosuppressant. The charges, encompassing 136 individual patent infringement claims, have been filed in a Delaware federal court.
Rinvoq, an immunosuppressant drug designed for treatment of conditions such as rheumatoid arthritis, is amongst the prime assets in AbbVie’s diversified pharmaceutical portfolio. Generics, or alternative brands offering comparable drug functionality at a lower cost, pose potential competition to branded pharmaceutical offerings, often after patent expiration or in regions not covered by the patent. In this context, AbbVie’s suit indicates their proactive stance against generic entry into the Rinvoq market segment.
The court filings serve as a window into the complex dynamics of the pharmaceutical industry, including the interplay between patent holders and companies looking to capitalize on promising drug markets with generic offerings. As an ongoing case, the implications and outcomes could potentially influence strategies of other market participants. Further details on the claims and the companies involved can be found in the original Law360 article.